Abstract: Disclosed is a process for the preparation of partricin alkyl esters which involves reacting partricin in a solvent with primary alkyl alcohols in the quantity of 5 to 1000 moles per mole of partricin in the presence of carbodiimides, and optionally in the presence of acylation catalysts and/or nitrogen bases or anhydrous acids.

Abstract: Disclosed is a process for the preparation of partricin alkyl esters which involves reacting partricin in a solvent with primary alkyl alcohols in the quantity of 5 to 1000 moles per mole of partricin in the presence of carbodiimides, and optionally in the presence of acylation catalysts and/or nitrogen bases or anhydrous acids.

Abstract: A stable complex of tomoxiprole with 2-hydroxypropyl-beta-cyclodextrin with fast dissolution rate and rapid absorption wherein amorphous tomoxiprole forms a complex with 2-hydroxypropyl-beta-cyclodextrin in about equimolecular ratio. The complex shows a remarkably faster dissolution rate and absorption with respect to crystalline tomoxiprole and is particularly suitable for the production of pharmaceutical oral dosage forms, such as tablets and capsules, where rapid onset of therapeutical action is required. A method of manufacture of the complex is also described and claimed.

Abstract: A stable complex of tomoxiprole with 2-hydroxypropyl-beta-cyclodextrin with fast dissolution rate and rapid absorption wherein amorphous tomoxiprole forms a complex with 2-hydroxypropyl-beta-cyclodextrin in about equimolecular ratio. The complex shows a remarkably faster dissolution rate and absorption with respect to crystalline tomoxiprole and is particularly suitable for the production of pharmaceutical oral dosage forms, such as tablets and capsules, where rapid onset of therapeutical action is required. A method of manufacture of the complex is also described and claimed.

Abstract: A novel process for the preparation of 10-0.times.0-10,11-dihydro-5H-dibenz(b,f)azepin-5-carboxamide (VI) consists of starting group 10-methoxy-5H-dibenz(b,f)azepine (IV) and subjecting compound (IV) to direct carbamoylation with isocyanic acid generated in situ from cyanates and acids and then subjecting the product to acid hydrolysis of the enol ether. An alternative process to obtain (VI) starts (IV) effecting the hydrolysis reaction before the carbamoylation. In this case the carbamoylating agent is chlorosulfonyl isocyanate.

Abstract: Compounds of formula I ##STR1## wherein: X is N or >C--F;Y is N, >C--F or >CH;R is a C.sub.1 -C.sub.5 alkyl or C.sub.3 -C.sub.6 cycloalkyl group;R.sub.1 is selected from the group consisting of a chlorine atom, an amino group or a group of formula:R.sup.2 --CH.dbd.N--wherein R.sub.2 is a C.sub.1 -C.sub.5, straight or branched aliphatic residue or an optionally substituted aromatic or heteroaromatic residue,and addition salts thereof with pharmaceutically acceptable bases or acids, prepared starting from the corresponding compounds wherein R.sub.1 is hydrogen, by reaction with organic hypochlorites or nitrous acid, are endowed with favorable therapeutic properties.

Abstract: Compounds of formula I ##STR1## wherein R is a phenyl group; a phenyl group mono- or di-substituted by halogen atoms, methyl, methoxy, nitro, or trifluoromethyl group; or a 2-, 3- or 4-pyridyl group; and pharmaceutically acceptable acid addition salts thereof.Compounds I are prepared by reacting N-substituted piperazines with 1-(2',4'-dichloro-benzoylmetyl)-imidazole, optionally reducing thereafter the resulting enamines.Compounds I have antimycotic and antibacterial activities, higher than those of known comparison drugs.